MacroGenics
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- MacroGenics
- Company name
- MacroGenics
- Organisation type
- Industry
- Registered legal name
- MacroGenics, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001125345
- Legal Entity Identifier (LEI)
- 5493001KJQUA83L8MH79
Related records
Trials (53)
- A Study of Lorigerlimab in Participants With Advanced Solid Tumors
- A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of MGC028 in Participants With Advanced Solid Tumors
- A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
- A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
- A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
- A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
- Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
- Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
- Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
- First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
- Flotetuzumab Expanded Access Program
- Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)